WWM
ESPR

WT Wealth Management’s Esperion Therapeutics ESPR Stock Holding History

WT Wealth Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,100
Closed -$26.8K – 139
2025
Q3 		$26.8K Hold
10,100
– – 0.01% 139
2025
Q2 		$9.94K Hold
10,100
– – ﹤0.01% 147
2025
Q1 		$14.5K Hold
10,100
– – ﹤0.01% 124
2024
Q4 		$22.2K Hold
10,100
– – 0.01% 134
2024
Q3 		$20.6K Hold
10,100
– – 0.01% 129
2024
Q2 		$22.4K Hold
10,100
– – 0.01% 121
2024
Q1 		$27.1K Hold
10,100
– – 0.01% 111
2023
Q4 		$30.2K Hold
10,100
– – 0.01% 108
2023
Q3 		$9.9K Buy
+10,100
New +$14.6K ﹤0.01% 104

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

WT Wealth Management's ESPR Position: Q4 2025 in Review

WT Wealth Management sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 10,100 shares — an estimated $26.8K sold.

WT Wealth Management first reported a position in ESPR in Q3 2023 and held it in 9 quarters. The position peaked at $30.2K in Q4 2023. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • WT Wealth Management reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • WT Wealth Management sold 10,100 Esperion Therapeutics shares in Q4 2025, an estimated $26.8K.
  • WT Wealth Management first reported a position in Esperion Therapeutics in Q3 2023 and held it in 9 quarters.
  • WT Wealth Management's Esperion Therapeutics position peaked at $30.2K in Q4 2023.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on WT Wealth Management's 13F filing for Q4 2025, filed 2 Feb 2026.